Aarti Pharmalabs Ltd's Q3FY25 Quarterly Results

Result Summary

• Aarti Pharmalabs Ltd reported a 17.4% quarter-on-quarter (QoQ) increase in its consolidated revenues for the quarter-ended Dec (Q3FY25). On a year-on-year (YoY) basis, it witnessed a growth of 20.6%.
• Its expenses for the quarter were up by 13.2% QoQ and 17.5% YoY.
• The net profit increased 35.5% QoQ and increased 40.2% YoY.
• The earnings per share (EPS) of Aarti Pharmalabs Ltd stood at 8.2 during Q3FY25.

Financial Statments for Q3FY25

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Aarti Pharmalabs Ltd is a company that operates in the pharmaceutical industry. It specializes in the development, manufacturing, and marketing of a diverse range of pharmaceutical products. Among its offerings are active pharmaceutical ingredients (APIs), intermediates, and specialty chemicals. The company is engaged in both domestic and international markets, providing solutions to various sectors within the healthcare industry. As of the latest available information, there are no specific recent developments or major announcements from the company included in the data provided.

Revenue

In the third quarter of fiscal year 2025 (Q3FY25), Aarti Pharmalabs Ltd reported a total income of ₹542.81 crores. This represents a significant increase of 17.4% on a quarter-over-quarter (QoQ) basis from the previous quarter (Q2FY25), where total income was ₹462.51 crores. Additionally, there is a 20.6% year-over-year (YoY) growth compared to the same quarter in the previous year (Q3FY24), which recorded a total income of ₹450.08 crores. The upward trajectory in revenue highlights a period of strong income generation for the company during this quarter.

Profitability

Aarti Pharmalabs Ltd demonstrated robust profitability in Q3FY25 with a profit before tax of ₹100.63 crores, marking a 40.2% increase QoQ from ₹71.77 crores in Q2FY25. On a YoY basis, the profit before tax rose by 36.3% from ₹73.82 crores in Q3FY24. The profit after tax for Q3FY25 was ₹73.99 crores, reflecting a 35.5% QoQ increase from ₹54.62 crores in the previous quarter and a 40.2% YoY rise from ₹52.76 crores in Q3FY24. Earnings per share (EPS) also improved to ₹8.20 in Q3FY25, up 36.7% QoQ from ₹6.00 and 41.4% YoY from ₹5.80 in Q3FY24.

Operating Metrics

In Q3FY25, total expenses for Aarti Pharmalabs Ltd reached ₹442.18 crores, an increase of 13.2% QoQ from ₹390.74 crores in Q2FY25, and a 17.5% YoY rise from ₹376.26 crores in Q3FY24. The tax expenses during Q3FY25 were ₹26.64 crores, which is a 55.3% increase compared to the previous quarter's ₹17.15 crores, and a 26.5% increase from ₹21.06 crores in the same quarter of the previous year. The company has maintained a strong operational performance with substantial growth in both income and profitability metrics, while managing an increase in expenses and taxes effectively during this period.